Evidence-based recommendations on vanzacaftor-tezacaftor-deutivacaftor (Alyftrek) for treating cystic fibrosis in people 6 years and over with an F508del mutation in the cystic fibrosis transmembrane ...

How NICE International is supporting evidence-based decision-making through the Regulatory Partnership for Growth Fund ...

After four years of transformational leadership, NICE CEO Dr Sam Roberts will step down at the end of the year to support her children through a difficult time.

Browse the complete list of all our published health and social care guidance, including guidelines, NICE advice and quality standards ...

COVID-19 All NICE products on COVID-19. Includes any guidance and advice. Published products on this topic (13) ...

Chronic kidney disease: early identification and management of chronic kidney disease in adults in primary and secondary care Clinical guideline CG73 Published: 24 September 2008 ...

This guideline covers managing colorectal (bowel) cancer in people aged 18 and over. It aims to improve quality of life and survival for adults with colorectal cancer through management of local ...

Dostarlimab with platinum-based chemotherapy for treating advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency Technology appraisal guidance ...

COVID-19 rapid guideline: reducing the risk of venous thromboembolism in over 16s with COVID-19 NICE guideline NG186 Published: 20 November 2020 ...

This guideline covers parenteral nutrition (intravenous feeding) for babies born preterm, up to 28 days after their due birth date and babies born at term, up to 28 days after their birth. Parenteral ...

Evidence-based recommendations on dabrafenib (Tafinlar) plus trametinib (Mekinist) for BRAF V600 mutation-positive advanced non-small-cell lung cancer in adults. Commercial arrangement There is a ...